{"id":"W4397009139","doi":"10.1038/s41591-024-02977-w","title":"p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Nerve injury and regeneration","field":"Neuroscience","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"National Institute on Aging; Canadian Institutes of Health Research; Genentech; National Institutes of Health; IXICO; National Institute of General Medical Sciences; H. Lundbeck A/S; Servier; Göteborgs Universitet; Alzheimer's Drug Discovery Foundation; Karolinska Institutet; Vetenskapsrådet; Eisai; Bristol-Myers Squibb; Government of Ontario; Northern California Institute for Research and Education; Pfizer; Biogen; BioClinica; Fondation pour la Recherche sur Alzheimer; Alzheimer's Society; University of Southern California; Hjärnfonden; F. Hoffmann-La Roche; Government of Canada; U.S. Department of Defense; Eli Lilly and Company; Medizinische Universität Graz; Alzheimer's Association; Karl-Franzens-Universität Graz; U.S. Department of Health and Human Services; Foundation for the National Institutes of Health","keywords":"Placebo; Clinical endpoint; Tolerability; Medicine; Randomized controlled trial; Clinical trial; Internal medicine; Oncology; Alzheimer's disease; Pharmacology; Adverse effect; Pathology; Disease","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001103307,0.0002680594,0.0007189892,0.0004477999,0.0001067423,0.00006861155,0.0001730573,0.0002023248,0.0002269985],"category_scores_gemma":[0.003204903,0.0001683796,0.0001672454,0.0007025387,0.0001126974,0.000223047,0.0000280473,0.0007427991,0.0000555582],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004644873,"about_ca_system_score_gemma":0.00008753558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001092257,"about_ca_topic_score_gemma":0.00000637072,"domain_scores_codex":[0.9970188,0.0008136341,0.0006130568,0.000674272,0.0006041857,0.0002760958],"domain_scores_gemma":[0.9985097,0.000863332,0.00008704242,0.0002686162,0.00004861879,0.0002226983],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7954218,0.0001235297,2.248812e-7,0.00001739276,0.00002049814,0.00008475853,0.0001992195,0.001693055,0.1908622,0.003291779,0.005165246,0.00312037],"study_design_scores_gemma":[0.7609252,0.000375838,0.000002362992,0.0002019251,0.0001769433,0.000003880714,0.000003823524,0.1940171,0.04003409,0.0009693687,0.003094875,0.0001946355],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9403451,0.006580916,0.001913406,0.03591106,0.007991329,0.006537953,0.00003811317,0.0002154817,0.0004666113],"genre_scores_gemma":[0.9920644,0.0001171532,0.00007818804,0.003211156,0.002606839,0.0005660845,0.00004295311,0.0000345968,0.001278675],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.192324,"threshold_uncertainty_score":0.6866319,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03304644434149519,"score_gpt":0.3556142142898926,"score_spread":0.3225677699483975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}